VimRx: FIPCO or Financier?
Executive Summary
VimRx's acquisition of Baxter's immunotherapy business is being touted by company officials as part of its transformation from a research-stage biotech to a fully integrated commercial enterprise. But others aren't so sure, saying the deal was driven more by Baxter's need to get the high R&D costs associated with its immunotherapy business off its books.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.